Department of Neurochemistry, Institute of Psychiatry and Neurology, 9 Sobieskiego Street, 02-957, Warsaw, Poland.
Department of Molecular and Cellular Neurobiology, Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur Street, 02-093, Warsaw, Poland.
Pharmacol Rep. 2023 Feb;75(1):85-98. doi: 10.1007/s43440-022-00443-3. Epub 2022 Dec 31.
Long-term cocaine exposure leads to dysregulation of the reward system and initiates processes that ultimately weaken its rewarding effects. Here, we studied the influence of an escalating-dose cocaine regimen on drug-associated appetitive behavior after a withdrawal period, along with corresponding molecular changes in plasma and the prefrontal cortex (PFC).
We applied a 5 day escalating-dose cocaine regimen in rats. We assessed anxiety-like behavior at the beginning of the withdrawal period in the elevated plus maze (EPM) test. The reinforcement properties of cocaine were evaluated in the Conditioned Place Preference (CPP) test along with ultrasonic vocalization (USV) in the appetitive range in a drug-associated context. We assessed corticosterone, proopiomelanocortin (POMC), β-endorphin, CART 55-102 levels in plasma (by ELISA), along with mRNA levels for D2 dopaminergic receptor (D2R), κ-receptor (KOR), orexin 1 receptor (OX1R), CART 55-102, and potential markers of cocaine abuse: miRNA-124 and miRNA-137 levels in the PFC (by PCR).
Rats subjected to the escalating-dose cocaine binge regimen spent less time in the cocaine-paired compartment, and presented a lower number of appetitive USV episodes. These changes were accompanied by a decrease in corticosterone and CART levels, an increase in POMC and β-endorphin levels in plasma, and an increase in the mRNA for D2R and miRNA-124 levels, but a decrease in the mRNA levels for KOR, OX1R, and CART 55-102 in the PFC.
The presented data reflect a part of a bigger picture of a multilevel interplay between neurotransmitter systems and neuromodulators underlying processes associated with cocaine abuse.
长期可卡因暴露会导致奖励系统失调,并启动最终削弱其奖励效应的过程。在这里,我们研究了在戒断期间,递增剂量可卡因方案对与药物相关的食欲行为的影响,以及血浆和前额叶皮层(PFC)中相应的分子变化。
我们在大鼠中应用了 5 天递增剂量可卡因方案。我们在戒断期开始时在高架十字迷宫(EPM)测试中评估焦虑样行为。在条件性位置偏好(CPP)测试中评估可卡因的强化特性,并在与药物相关的环境中评估食欲范围内的超声发声(USV)。我们通过酶联免疫吸附试验(ELISA)评估血浆中的皮质酮、前阿黑皮素原(POMC)、β-内啡肽、CART 55-102 水平,以及 PFC 中的 D2 多巴胺能受体(D2R)、κ-受体(KOR)、食欲素 1 受体(OX1R)、CART 55-102 的 mRNA 水平,以及潜在的可卡因滥用标志物:miRNA-124 和 miRNA-137 水平(通过 PCR)。
接受递增剂量可卡因狂欢方案的大鼠在可卡因配对隔室中花费的时间更少,并且表现出较少的食欲性 USV 发作。这些变化伴随着血浆中皮质酮和 CART 水平的降低,POMC 和 β-内啡肽水平的升高,以及 PFC 中 D2R 和 miRNA-124 水平的 mRNA 升高,但 KOR、OX1R 和 CART 55-102 的 mRNA 水平降低。
所呈现的数据反映了神经递质系统和神经调质之间多层次相互作用的一部分,这些相互作用是与可卡因滥用相关的过程的基础。